| Model: | - |
|---|---|
| Brand: | - |
| Origin: | - |
| Category: | Chemicals / Biochemical |
| Label: | Mirabegron , Mirabegron API |
| Price: |
-
|
| Min. Order: | - |
| Last Online:28 Apr, 2023 |
Product Description
| Product Name: | Mirabegron |
| Synonyms: | 2-AMino-N-[4-[2-[[(2R)-2-hydroxy-2-phenyl-ethyl]aMino]-ethyl]phenyl]-4-thiazoleacetaMide;2-(2-aMino-1,3-thiazol-4-yl)-N-(4-{2-[(2-hydroxy-2-phenylethyl)aMino]ethyl}phenyl)acetaMide;(2R)-2-(2-AMinothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)aMino]ethyl]acetic Acid Anilide;4-Thiazoleacetamide, 2-amino-N-(4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)-;Mirabegron;N-(4-(2-(2-hydroxy-2-phenylethylamino)ethyl)phenyl)-2-(2-aminothiazol-4-yl)acetamide;YM 178;Mirabegron(YM 178) |
| CAS: | 223673-61-8 |
| MF: | C21H24N4O2S |
| MW: | 396.51 |
| EINECS: | 800-126-3 |
Mirabegron is an orally active β3-adrenoceptor agonist currently in development by Astellas Pharma for the treatment of overactive bladder (OAB). The drug is a nanomolar EC50 antagonist against human β3-AR biochemical assays with good selectivity over b1- and β2-ARs. Mirabegron demonstrates a novel mechanism by targeting the β3-AR for bladder relaxation to help manage OAB symptoms such as increased urinary urgency and frequency and urgency incontinence. However, mirabegron is a cytochrome P450 2D6 inhibitor, and it raises a concern for drug-drug interaction with concomitant administration of other cytochrome P450 2D6 substrates.
Potent bladder relaxant and reagent for diabetes remedy.;Labeled Mirabegron, intended for use as an internal standard for the quantification of Mirabegron by GC- or LC-mass spectrometry.